Therefore, the purpose of the current study was to assess the influence of potassium canrenoate, an intravenous formula of mineralocorticoid receptor antagonist, on the change in inflammatory markers in patients with severe COVID-19-associated pneumonia. This evidence concerns the gene NR3C2 and COVID-19.